A panel of three markers hyper- And hypomethylated in urine sediments accurately predicts bladder cancer recurrence

Clinical Cancer Research

Volumn 20, Issue 7, 2014, Pages 1978-1989

  Su, Sheng Fang ^a,b   De Castro Abreu, André Luís ^a   Chihara, Yoshitomo ^a   Tsai, Yvonne ^a   Andreu Vieyra, Claudia ^a   Daneshmand, Siamak ^a   Skinner, Eila C ^c   Jones, Peter A ^a   Siegmund, Kimberly D ^b   Liang, Gangning ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER RECURRENCE; CARCINOGENESIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYSTOSCOPY; DNA METHYLATION; FEMALE; GENE INACTIVATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PYROSEQUENCING; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; URINALYSIS; URINE SEDIMENT; VALIDATION PROCESS; VERY ELDERLY; BLADDER TUMOR; CANCER STAGING; GENETICS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; URINE;

TUMOR MARKER;

ADULT; AGED; CARCINOGENESIS; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84898753297     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2637     Document Type: Article

References (48)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36.
2. Morgan TM, Clark PE. Bladder cancer. Curr Opin Oncol 2010;22:242-9.
3. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bröhle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997-1008.
4. Sobin LH, Gospodarowicz MK, Christian W. TNM classification of malignant tumours. 7th ed. Wiley-Blackwell; 2009.
5. Shelley MD, Mason MD, Kynaston H. Intravesical therapy for superficial bladder cancer: A systematic review of randomised trials and meta-analyses. Cancer Treat Rev 2010;36:195-205.
6. Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodríguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000;164:680-4. (Pubitemid 30637601)
7. Lintula S, Hotakainen K. Developing biomarkers for improved diagnosis and treatment outcome monitoring of bladder cancer. Expert Opin Biol Ther 2010;10:1169-80.
8. Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1-48.
9. Parker J, Spiess PE. Current and emerging bladder cancer urinary biomarkers. ScientificWorldJournal 2011;11:1103-12.
10. Reinert T. Methylation markers for urine-based detection of bladder cancer: The next generation of urinary markers for diagnosis and surveillance of bladder cancer. Adv Urol 2012;2012:503271.
11. Jones PA. Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat Rev Genet 2012;13:484-92.
12. Wolff EM, Chihara Y, Pan F, Weisenberger DJ, Siegmund KD, Sugano K, et al. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res 2010;70:8169-78.
13. Wolff EM, Byun HM, Han HF, Sharma S, Nichols PW, Siegmund KD, et al. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet 2010;6:e1000917.
14. Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T, et al. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res 2010;70:1430-40.
15. Ushijima T, Hattori N. Molecular pathways: Involvement of Helicobacter pylori-triggered in flammation in the formation of an epigenetic field defect, and its usefulness as cancer risk and exposure markers. Clin Cancer Res 2012;18:923-9.
16. Wolff EM, Liang G, Jones PA. Mechanisms of Disease: Genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2005;2:502-10. (Pubitemid 41594404)
17. Laird PW. The power and the promise ofDNAmethylation markers. Nat Rev Cancer 2003;3:253-66.
18. Kim WJ, Kim YJ. Epigenetic biomarkers in urothelial bladder cancer. Expert Rev Mol Diagn 2009;9:259-69.
19. Reinert T, Modin C, Castano FM, Lamy P, Wojdacz TK, Hansen LL, et al. Comprehensive genome methylation analysis in bladder cancer: Identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res 2011;17:5582-92.
20. Vallot C, Stransky N, Bernard-Pierrot I, Hérault A, Zucman-Rossi J, Chapeaublanc E, et al. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst 2011;103:47-60.
21. Friedrich MG, Weisenberger DJ, Cheng JC, Chandrasoma S, Siegmund KD, Gonzalgo ML, et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 2004;10:7457-65. (Pubitemid 39557507)
22. Seifert HH, Schmiemann V, Mueller M, Kazimirek M, Onofre F, Neuhausen A, et al. In situ detection of global DNA hypomethylation in exfoliative urine cytology of patients with suspected bladder cancer. Exp Mol Pathol 2007;82:292-7. (Pubitemid 46686656)
23. Kim YK, Kim WJ. Epigenetic markers as promising prognosticators for bladder cancer. Int J Urol 2009;16:17-22.
24. Chihara Y, Kanai Y, Fujimoto H, Sugano K, Kawashima K, Liang G, et al. Diagnostic markers of urothelial cancer based on DNA methylation analysis. BMC Cancer 2013;13:275.
25. De Carvalho DD, Sharma S, You JS, Su SF, TaberlayPC, Kelly TK, et al. DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell 2012;21:655-67.
26. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, et al. AJCC Cancer Staging Manual, 7th ed. New York: Springer-Verlag; 2010.
27. Kamat AM, Karam JA, Grossman HB, Kader AK, Munsell M, Dinney CP. Prospective trial to identify optimal bladder cancer surveillance protocol: Reducing costs while maximizing sensitivity. BJU Int 2011;108:1119-23.
28. Whitson J, Berry A, Carroll P, Konety B. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int 2009;104:336-9.
29. Kamat AM, Dickstein RJ, Messetti F, Anderson R, Pretzsch SM, Gonzalez GN, et al. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: Results of a prospective trial. J Urol 2012;187:862-7.
30. Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 2011;60:484-92.
31. Steiner G, Schoenberg MP, Linn JF, Mao L, Sidransky D. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 1997;3:621-4. (Pubitemid 27264970)
32. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010;5:e13821.
33. Costa VL, Henrique R, Danielsen SA, Duarte-Pereira S, Eknaes M, Skotheim RI, et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res 2010;16:5842-51.
34. Chung W, Bondaruk J, Jelinek J, Lotan Y, Liang S, Czerniak B, et al. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prev 2011;20:1483-91.
35. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 2004;10:1887-93. (Pubitemid 38375544)
36. Lin HH, Ke HL, Huang SP, Wu WJ, Chen YK, Chang LL. Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine. Urol Oncol 2010;28:597-602.
37. Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002;8:464-70. (Pubitemid 34193966)
38. Oliveira AI, Jerónimo C, Henrique R. Moving forward in bladder cancer detection and diagnosis: The role of epigenetic biomarkers. Expert Rev Mol Diagn 2012;12:871-8.
39. Friedrich MG, Chandrasoma S, Siegmund KD, Weisenberger DJ, Cheng JC, Toma MI, et al. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer 2005;41:2769-78. (Pubitemid 41607571)
40. Tada Y, Wada M, Taguchi K, Mochida Y, Kinugawa N, Tsuneyoshi M, et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 2002;62:4048-53. (Pubitemid 34791073)
41. Zhao Y, Guo S, Sun J, Huang Z, Zhu T, Zhang H, et al. Methylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a Chinese population. PLoS One 2012;7:e35175.
42. Negraes PD, Favaro FP, Camargo JL, Oliveira ML, Goldberg J, Rainho CA, et al. DNA methylation patterns in bladder cancer and washing cell sediments: A perspective for tumor recurrence detection. BMC Cancer 2008;8:238.
43. Reinert T, Borre M, Christiansen A, Hermann GG, Orntoft TF, Dyrskjøt L. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation. PLoS ONE 2012;7:e46297.
44. Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 2006;98:996-1004. (Pubitemid 44288164)
45. Rouprêt M, Hupertan V, Yates DR, Comperat E, Catto JW, Meuth M, et al. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. BJU Int 2008;101:1448-53. (Pubitemid 351623989)
46. Zuiverloon TC, van der Aa MN, van der Kwast TH, Steyerberg EW, Lingsma HF, Bangma CH, et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res 2010;16:3011-8.
47. Brems-Eskildsen AS, Zieger K, Toldbod H, Holcomb C, Higuchi R, Mansilla F, et al. Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts. BMC Cancer 2010;10:646.
48. Zuiverloon TC, Beukers W, van der Keur KA, Munoz JR, Bangma CH, Lingsma HF, et al. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. BJU Int 2012;109:941-8.